Broad cellular components – regimen-level, non-specific

The term "Broad cellular components – regimen-level, non-specific" is a nomenclature used in pharmaceutical intelligence databases to categorize drugs and treatment regimens that lack a single, defined molecular target [1]. This classification typically applies to traditional cytotoxic chemotherapies, such as alkylating agents and antimetabolites, which exert their therapeutic effects by broadly damaging cellular DNA or inhibiting general metabolic pathways required for cell division [2][3]. Unlike targeted therapies that interact with specific proteins or receptors, these "regimen-level" interventions affect a wide array of cellular components simultaneously to induce cell death in rapidly proliferating populations [4]. Consequently, these treatments are characterized by a broad range of systemic toxicities and are often used as foundational components of multi-drug cancer protocols [5]. In clinical practice, these regimens remain a cornerstone of treatment for many malignancies despite the rise of targeted agents, and this designation serves to distinguish non-specific cytotoxic approaches from precision medicine in clinical trial reporting [1][5]. Sources: [1] Citeline Pharmaprojects Target Classification; [2] National Cancer Institute Dictionary of Cancer Terms; [3] Goodman & Gilman's The Pharmacological Basis of Therapeutics; [4] American Cancer Society; [5] DeVita & Chu (2008) Cancer Research.

Other names

Non-specific cytotoxic therapyBroad-spectrum cellular targetingRegimen-level targetingNon-targeted chemotherapy

Non-specific disruption of cellular replication and maintenance through DNA damage, antimetabolite interference, or microtubule inhibition.